Michael Grey

Michael has served on ther board of directors since September 2011 and as lead independent director of the company since August 2012. He is executive chairman of Amplyx Pharmaceuticals, Inc., chairman and chief executive officer of Reneo Pharmaceuticals, Inc. and a venture partner at Pappas Ventures. Michael most recently served as president and chief executive officer at Lumena Pharmaceuticals, which was acquired by Shire plc in June 2014. He has more than 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc. For approximately 20 years, Michael also serves on the board of directors of BioMarin Pharmaceutical Inc., Mirati Therapeutics, Inc., Amplyx Pharmaceuticals, Inc., Balance Therapeutics, Inc. and Biothera Pharmaceuticals, Inc.

Michael received a Bachelor of Science in Chemistry from the University of Nottingham in the United Kingdom.